Medicare Part D to Mandate Cheaper Generics & Biosimilars by 2028, Lowering Senior Drug Costs

Alright, let's talk about something that hits close to home for a lot of folks, especially those watching their budgets: prescription drug costs. This new piece of legislation, officially dubbed the "Ensuring Access to Lower-Cost Medicines for Seniors Act," is looking to shake things up for Medicare Part D plans starting in 2028. The big idea? Make it easier and cheaper for seniors to get their hands on generic drugs and biosimilars—those lower-cost, often equally effective alternatives to expensive brand-name meds.

Your Medicine Cabinet, Post-2028

So, what does this actually mean for your monthly pharmacy run? Currently, Medicare Part D and Medicare Advantage plans with prescription drug coverage (MAPD plans) have some wiggle room in what they cover and how much they charge. But come January 1, 2028, this bill tightens the reins. If a plan covers a brand-name drug, it must also cover every generic version of that drug that has a lower wholesale acquisition cost. Same deal for biologics: if a plan covers a brand-name biologic, it has to cover at least one biosimilar version that's cheaper. This means more choices for you and, hopefully, less sticker shock at the counter. The Secretary of Health and Human Services will be laying down the specific rules on how to figure out what counts as 'lower cost' and how these changes roll out, ensuring there's a clear roadmap for plans to follow.

Cutting Down on Cost-Sharing

Beyond just getting these drugs on the formulary, the bill also targets your wallet directly. If your plan uses a tiered cost-sharing system (you know, where different drugs fall into different price categories), it will be required to have at least one tier just for generics and biosimilars. And here's the kicker: the copayment for that tier has to be either zero or at least $20 less than the lowest brand-name drug tier. Think about that—a guaranteed discount of at least twenty bucks, or even free, for many common medications. Even for high-cost specialty drugs, there's a provision for a second specialty tier for generics and biosimilars with a coinsurance rate that's at least 5 percentage points lower than other specialty tiers. This is a pretty clear signal that the goal is to drive down out-of-pocket costs for seniors, which is a huge deal when you're on a fixed income.

No More Games: Access Guaranteed

Ever feel like your insurance company is playing games to push you towards a more expensive drug? This bill tries to shut that down. Plans cannot impose restrictions like prior authorization, utilization management, or step therapy on these required generic drugs or biosimilars if those restrictions are tougher than what they apply to the brand-name version. They also can't use these tactics to make the brand-name drug look like the preferred option. This is about ensuring that when a cheaper, equally effective option is available, you can actually get it without jumping through extra hoops. Plus, it tackles deductibles: plans can't apply a deductible to generics or biosimilars unless the same or a greater deductible applies to all other covered drugs, preventing sneaky ways to make you pay more upfront for the cheaper options. For those keeping an eye on their budgets, this means more predictable and potentially much lower costs for essential medications. It's a move that aims to put more power in the hands of the patient and less in the complex formulary designs of insurance companies.